SCHEMBL3588890

SCHEMBL3588890

Cc1[c]ccc(C)c1N1CCN(C)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2C P18825 4/20 0.36
KMT2A Q03164 2/20 0.36
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
GFER P55789 1/20 0.36
PTK2B Q14289 1/20 0.36
ESR2 Q92731 1/20 0.36
HTR3A P46098 3/20 0.36
HTR3E A5X5Y0 2/20 0.36
HTR3B O95264 2/20 0.36
HTR3D Q70Z44 2/20 0.36
HTR3C Q8WXA8 2/20 0.36
ACHE P22303 1/20 0.35
HRH4 Q9H3N8 3/20 0.34
ADRA2A P08913 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7552901 0.80 DRD3 (0.46) KMT2AKDM4EALDH1A1GFERACHE
SCHEMBL3601316 0.74 ADRA2C (0.42) ADRA2CKMT2AKDM4EALDH1A1GAA
SCHEMBL14543377 0.74 ALDH1A1 (0.53) ADRA2CKMT2AKDM4EALDH1A1GAA
SCHEMBL16463118 0.72 ADRA2C (0.43) ADRA2CKMT2AKDM4EALDH1A1GAA
SCHEMBL1449846 0.70 ADRA2C (0.50) ADRA2CKMT2AKDM4EALDH1A1GAA
SCHEMBL20180553 0.67 DRD2 (0.56) ADRA2CKMT2AKDM4EALDH1A1MAPT
SCHEMBL188362 0.67 ADRA2C (0.42) ADRA2CKMT2AKDM4EALDH1A1GAA
SCHEMBL21447974 0.67 ALDH1A1 (0.46) ADRA2CKMT2AKDM4EALDH1A1GAA
SCHEMBL21448009 0.67 HRH4 (0.43) ADRA2CKMT2AKDM4EALDH1A1GAA
SCHEMBL5884761 0.67 HTR3A (0.51) ADRA2CKMT2AKDM4EALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029636-A1 Lck inhibitors NOVARTIS AG (CH) 2010-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029636-A1 Lck inhibitors LCK, ZAP70, FYN ADRA2C 3317/4885KMT2A 1321/4885KDM4E 557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.